OSI Pharmaceuticals, Inc.

1 Bioscience Park Drive,
Farmingdale, New York 11735
United States,
(631)962-0600

OSI Pharmaceuticals Inc. is an oncology drug discovery and translational research company, primarily focused on the discovery of molecular targeted therapies.

M&A Summary

Buy vs Sell

Year ≤ '07 '08 '09 '10 '11 '12 T
Buy (0.0/yr) # 3 - - - - - 3
vol $1.2B $1.2B
Sell (0.2/yr) # - - - - - 1 1
vol $22M $22M
  4

Top M&A Advisors

Financial Deals
Sign-up to View
1
Legal Deals
Join to Access.

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest Eyetech Pharmaceuticals, Inc.
$935M (2005-08-22)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View
Largest Eyetech Pharmaceuticals, Inc.
$22M (2012-03-01)

OSI Pharmaceuticals was acquired by Astellas Pharma on June 09, 2010.

OSI Pharmaceuticals has acquired 3 companies of its own. A total of 1 acquisition came from private equity firms. It has also divested 1 asset.

OSI Pharmaceuticals’ largest acquisition to date was in 2005, when it acquired Eyetech Pharmaceuticals for $935M. It’s largest disclosed sale occurred in 2012, when it sold Eyetech Pharmaceuticals to Valeant Pharmaceuticals International for $22M. OSI Pharmaceuticals has acquired in 3 different US states. The Company’s most targeted sectors include life science (100%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 415 life science companies that have made at least 1 acquisition, 25 have acquired at least 5 companies, and 3 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 25 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 4 platform acquisitions.

Join Mergr and gain access to OSI Pharmaceuticals’ M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.3K Private Equity Firms
  • 112K M&A Transactions
  • 121K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 38K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.